Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

Our study makes a case for clinicians to include high-intensity lower body RT in the treatment of peripheral artery disease. Trial registration number CRD42017081184. This review was registered with ...